Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination

• Status: Recruiting
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of our work is to compare the antiproteinuric efficacy of ACEI monotherapy, Selective MRA monotherapy and their combination in mildly hypertensive patients with type 2 diabetes mellitus and microalbuminuria

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Ramipril

Criteria

Inclusion Criteria:

• Adult male and non-pregnant female patients with established diagnosis of type 2 DM at least five years ago with glycosylated hemoglobin (HbA1c) ≤ 8.5%

• Age 30-80 Y

• Stage 1 hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) and microalbuminuria diagnosed by measuring Urinary albumin/creatinine ratio (UACR) . Microalbuminuria was defined at a level between (30-300 mg/g)

• Patients included in our study had never been treated with ACEIs, ARBs or aldosterone antagonists, serum potassium level ≥ 3.5 and ≤ 5.0 mmol/L before randomization with estimated glomerular filtration rate (e GFR) ≥50 mL/min/1.73 m2

Exclusion Criteria:

• Patients with type 1 diabetes mellitus

• Patients with BP ≥ 160/100 mmHg

• Patients with secondary hypertension

• Non-diabetic nephropathy including (chronic glomerulonephritis, polycystic kidney disease and nephrosclerosis),

• Confirmed bilateral renal artery stenosis or stenosis of the renal artery in solitary functioning kidney

• History of New York Heart Association functional class III and IV heart failure

• Patients with rapid progression of kidney disease and women who were pregnant, breast-feeding, or planning to become pregnant during the study period